Parkman Healthcare Partners LLC Purchases 93,201 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Parkman Healthcare Partners LLC raised its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 21.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 532,172 shares of the company’s stock after buying an additional 93,201 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.70% of Nurix Therapeutics worth $10,026,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. US Bancorp DE raised its holdings in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after purchasing an additional 842 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Nurix Therapeutics in the fourth quarter valued at $87,000. Summit Investment Advisors Inc. boosted its position in shares of Nurix Therapeutics by 13.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock valued at $138,000 after acquiring an additional 877 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Nurix Therapeutics in the fourth quarter valued at about $164,000. Finally, Nomura Holdings Inc. bought a new stake in Nurix Therapeutics during the fourth quarter worth about $198,000.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on NRIX. Leerink Partnrs raised shares of Nurix Therapeutics to a “hold” rating in a research report on Monday, March 17th. Royal Bank of Canada upped their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Stifel Nicolaus cut their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th. Stephens reaffirmed an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Finally, Wells Fargo & Company lowered their target price on Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, April 9th. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.44.

Insider Buying and Selling

In other news, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now directly owns 61,516 shares in the company, valued at $707,434. The trade was a 5.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the sale, the chief financial officer now owns 33,724 shares in the company, valued at $382,092.92. The trade was a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,838 shares of company stock worth $221,500 in the last ninety days. Corporate insiders own 7.40% of the company’s stock.

Nurix Therapeutics Stock Down 4.4%

Shares of NRIX stock opened at $9.73 on Wednesday. The company has a market cap of $741.78 million, a price-to-earnings ratio of -3.37 and a beta of 2.23. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56. The firm has a 50 day moving average of $11.32 and a 200-day moving average of $17.18.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The company had revenue of $18.45 million for the quarter, compared to analysts’ expectations of $12.78 million. During the same period last year, the business earned ($0.76) EPS. Analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.